COMPANY

Sur180 Therapeutics, Inc.

Keywords: endometriosis

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $1.14M (SBIR Phase II 5R44HD109055-03, continuation, notice Jun 3, 2026). NIH RePORTER 5R44HD109055-03 (Jun 3, 2026)
Evidence (1 event)
- Jun 3, 2026 · NIH RePORTER 5R44HD109055-03
  Organization: SUR180 THERAPEUTICS, LLC; City/State: MCALLEN, TX; Project number: 5R44HD109055-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 1140501; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Phase II- Repurposing CRH antagonists for the treatment of endometriosis; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Jun 3, 2026 Grant Government grant — SBIR: $1.14M (annual award, as published), announced Jun 3, 2026. Agency: NIH/NICHD. Source: government award database. source ↗
May 16, 2025 Grant Government grant — SBIR: $1.24M (annual award, as published), announced May 16, 2025. Agency: NIH/NICHD. Source: government award database. source ↗

Last 2 years.

Jun 3, 2026 Government grant — SBIR: $1.14M (annual award, as published), announced Jun 3, 2026. Agency: NIH/NICHD. Source: government award database. source ↗
May 16, 2025 Government grant — SBIR: $1.24M (annual award, as published), announced May 16, 2025. Agency: NIH/NICHD. Source: government award database. source ↗